Skip to main content

Table 2 Anti-phospholipid antibody (aPL) positives by line immunoassay (LIA) and consensus criteria enzyme-linked immunosorbent assay (ELISA) in 95 subjects including 34 patients with anti-phospholipid syndrome (APS), 41 with systemic autoimmune rheumatic disease (SARD), and 20 healthy subjects (children) (HS) as control groups

From: Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

ELISA

LAC

TP

aD1/aD4–5

LIA

 

ACL

2GPI

Any aPL

aCL

aPA

aPC

aPE

aPG

aPI

aPS

aAnV

2GPI

aPT

Any aPL

G

M

G

M

G

M

G

M

G

M

G

M

G

M

G

M

G

M

G

M

G

M

G

M

APS

n = 34

24

21

30

18

31

24

14

28

27

13

24

10

0

0

0

0

18

1

7

2

30

16

2

5

27

17

17

5

33

SARD

n = 41

18***

19

25**

23

33

18***

8

26

26

12

22

8

0

0

0

0

4*

0

3

2

27***

9***

0

3

22***

12

7**

3

32

HS

n = 20

NA

0#

0#

1##

1#

NA

NA

NA

1#

0##

0#

0####

0

0

0

1

0#

1

0####

0

0#

0##

0

0

1#

0#

1##

1

3#

  1. Comparison of APS vs SARD: *p < 0.001, **p < 0.01, ***p < 0.05
  2. Comparison of APS vs HC: #p < 0.0001, ##p < 0.001, ###p < 0.01, ####p < 0.05
  3. LAC and TP testing was conducted for 33 APS and 39 SARD patients only
  4. aβ2GPI anti-beta2 glycoprotein I, aCL anti-cardiolipin, aD1 anti-domain 1, aD4–5 anti-domains 4 and 5, aPA anti-phosphatidic acid, aPC anti-phosphatidylcholine, aPE anti-phosphatidylethanolamine, aPG anti-phosphatidylglycerol, aPI anti-phosphatidylinositol, aPS anti-phosphatidyl-serine, aAnV anti-annexin V, aPT anti-prothrombin, LAC lupus anti-coagulant, TP triple positivity (aCL positive, aβ2GPI positive, LAC positive), NA not available